Akari Therapeutics PLC (AKTX)
2.01
-0.22
(-9.87%)
USD |
NASDAQ |
Nov 15, 16:00
2.01
0.00 (0.00%)
After-Hours: 16:32
Akari Therapeutics Free Cash Flow (Quarterly): -4.894M for June 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -4.894M |
March 31, 2024 | -4.044M |
June 30, 2023 | -4.694M |
March 31, 2023 | -4.88M |
June 30, 2022 | -8.574M |
March 31, 2022 | -5.050M |
December 31, 2021 | -5.004M |
September 30, 2021 | -1.559M |
June 30, 2021 | -4.866M |
March 31, 2021 | -7.418M |
December 31, 2020 | -4.233M |
September 30, 2020 | -0.7042M |
June 30, 2020 | -4.274M |
March 31, 2020 | -7.740M |
December 31, 2019 | -3.464M |
September 30, 2019 | -4.910M |
June 30, 2019 | -4.772M |
March 31, 2019 | 0.2289M |
December 31, 2018 | -4.761M |
Date | Value |
---|---|
September 30, 2018 | -5.331M |
June 30, 2018 | -8.284M |
March 31, 2018 | -4.398M |
December 31, 2017 | -8.517M |
September 30, 2017 | -9.214M |
June 30, 2017 | -4.73M |
March 31, 2017 | -9.174M |
December 31, 2016 | -6.500M |
September 30, 2016 | -4.999M |
June 30, 2016 | -5.697M |
March 31, 2016 | -7.483M |
December 31, 2015 | -6.770M |
September 30, 2015 | 4.491M |
June 30, 2015 | -0.6975M |
March 31, 2015 | -1.988M |
December 31, 2014 | -0.668M |
September 30, 2014 | 3.567M |
June 30, 2014 | -2.328M |
March 31, 2014 | -2.048M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-8.574M
Minimum
Jun 2022
-0.7042M
Maximum
Sep 2020
-4.760M
Average
-4.866M
Median
Jun 2021
Free Cash Flow (Quarterly) Benchmarks
Adaptimmune Therapeutics PLC | 46.64M |
Biodexa Pharmaceuticals PLC | -- |
NuCana PLC | -1.569M |
Autolus Therapeutics PLC | -51.92M |
Genfit SA | -- |